Project Grant R21DE035321

Award Date 7/1/25
Completion Date 6/30/27
Dollars Obligated $422K
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $704,206 to Oregon Health & Science University (OHSU) to develop an "organ on-a-chip" model of oral cancer and bone invasion. The goal is to systematically manipulate, characterize, and validate tissue microenvironment variables linked to oral squamous cell carcinoma (OSCC) invasion into bone, elucidate...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), is providing $409,960.00 to Texas A&M University System Health Science Center to develop a human salivary gland-on-a-chip model. The goal is to create a platform that can faithfully replicate normal salivary gland function as well as model the effects of radiation-induced damage, in order to improve drug development efforts...
This $390,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to identify tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The key products and services to be delivered include: Developing a high-throughput, single-cell co-culture system to isolate individual tumor-killing T cells and identify their T cell receptors (TCRs). Performing...
This $429,114 federal Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) will fund the development and validation of a first-of-its-kind multi-tissue on-a-chip breast-skin platform. The platform will feature integrated blood and lymphatic vasculature to study the spatial and temporal processes of lymphovascular space invasion (LVSI), dermal lymphatic invasion (DLI), and skin metastasis in breast cancer. The central hypothesis is that the cross-talk...
This $598,332 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, will support research to investigate the role of the truncated TrkB isoform (TrkBT1) in oral cancer pain. The primary awardee, the University of Texas Health Science Center at San Antonio (UTHSCSA), will conduct studies to examine how TrkBT1 expressed in trigeminal sensory neurons and oral squamous cell carcinoma (OSCC)...
This federal Project Grant award of $429,000.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program. The grant supports research to determine the functional roles and mechanisms of the human microbiome and metabolome in the pathogenesis of oral squamous cell carcinoma (OSCC), a prevalent and lethal form of head and neck cancer. The research aims to 1) define OSCC-associated metagenomic and...
This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $434,170 to the University of Texas Health Science Center at Houston (UTHealth) to develop engineered bacterial in situ vaccines against oral cancer. The key products and services to be delivered under this grant include: 1) developing non-pathogenic E. coli bacteria that can be programmed to secrete the...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $808,264 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program to The Medical University of South Carolina. The grant aims to elucidate the mechanisms underlying filopodia-mediated intracellular uptake of a cell-penetrating peptide (RD3AD) complex carrying small interfering RNAs (siRNAs), and to determine its ability to target and deliver siRNAs to migrating/invading oral...
This federal Project Grant award of $685,594 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to leverage microsurgery and bioprinting techniques to improve vascularization and survival of 3D printed or bioprinted bone grafts for craniomaxillofacial reconstructive surgery. The key products and services to be delivered include: Developing a novel microsurgical "vascular micropuncture"...

This federal Project Grant award, titled "Engineering Oral Tumor Microcirculation: Blood and Lymphatic Capillary Network-Enabled Human Oral Tumor Microenvironment Chips for Preclinical Research", is funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The $421,625 award, effective from July 1, 2025 to June 30, 2027, will support the development of advanced tumor microenvironment chips (TME-chips) that incorporate perfusable blood and lymphatic capillary networks. These innovative systems aim to recreate the tumor microenvironment of oral squamous cell carcinoma (OSCC) with unprecedented accuracy, integrating 3D tumor spheroids to explore angiogenesis, lymphangiogenesis, and microcirculatory dynamics. The project, led by the Texas A&M Engineering Experiment Station (Tees), seeks to advance understanding of OSCC progression and resistance to therapies, ultimately providing a platform for preclinical drug testing, biomarker discovery, and the design of more effective therapeutic strategies.

Generated 8/5/25, 2:50 AM